

FOR IMMEDIATE RELEASE

February 29, 2016

AbbVie GK
Eisai Co., Ltd.

AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA[®], a Fully Human Anti-TNF- Monoclonal Antibody, in the Treatment of Polyarticular Juvenile Idiopathic Arthritis

- *Japan's Ministry of Health, Labour and Welfare cleared the condition for approval based on a review of an interim report of all-case surveillance on patients with polyarticular juvenile idiopathic arthritis*
- *The analysis results supported the previously established safety and efficacy of HUMIRA[®]*

AbbVie GK (Headquarters: Tokyo, President: James C. Feliciano, "AbbVie") and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance"

[Notes to editors]

1. Glossary of Terms

1) Polyarticular Juvenile Idiopathic Arthritis

Juvenile idiopathic arthritis (JIA)

